6.96 USD
▼-0.44-5.95%
盘后 7.01 +0.72%
2026-09-15
市值
$426.72M
市盈率
—
EPS
-2.88
股息率
—
52 周区间
3.78 – 13.67
成交量
1.07M
Beta
1.99
目标价
30.40
52W 低 3.7852W 高 13.67
价格走势
公司简介
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen...